1Park DJ, Lenz HJ. Determinants of chemosensitivity in gastric cancer[ J]. Curr Opin Pharmacol,2006,6(4 ) :337 - 344.
2Marsh S, Collie DES, Li T, et al. Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian population [ J]. Genomics, 1999,58 (3) :310 - 312.
3Kaneda S,Nalbantoglu J, Takeishi K, et al. Structural and functional analyse of the human thymidylate synthase gene[ J]. J Biol Chem, 1990,265 ( 33 ) : 20277 - 20284.
4Lincz LF, Scorgie FE, Garg MB, et al. Identification of a novd single nucleotide polymorphism in the first tandem repeat sequence of the thymidylate synthase 2R allele [ J]. Int J Cancer, 2007,120 (9) :1930 - 1934.
5Chen J, Hunter D J, Stampfer M J, et al. Polymorphism in the thymidylate synthase promoter enhancer region modifies the risk and survival of colorectal cancer [ J ]. Epidemiol Biomarkers Prey, 2003,12 ( 10 ) :958 - 962.
6Adleff V,Hitre E,koves L, et al. Heterozygote deficiency in thymidylate synthase promoter enhancer region polymorphism genotype distribution in Hungarian colorectal cancer patients[J]. Int J Cancer,2004,108(6) :852 -856.
8Graziano F, Kawakami K, Watanabe G, et al. Association of thymidylate synthase polymorphisms with gastric cancer susceptibility[J]. Int J Cancer,2004,112(6) :1010 - 1014.
9Mandola MV, Stoehlmacher J, Zhang W, et al. A 6bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels [ J]. Pharmacogenetics, 2004,14(5 ) :319 - 327.
10Merkelbach BS, Hans V, Mathiak M, et al. Associations between polymorphisms in the thymidylate synthase gene, the expression of thymidylate synthase mRNA and the microsatellite instability phenotype of colorectal cancer [ J ]. Oncol Rep,2004, 11(4) :839 -843.
二级参考文献36
1Allegra C. Thymidylate synthase levels: prognostic, predictive, or both? J Clin Oncol, 2002,20:1711-1713.
2Iacopetta B, Grieu F, Joseph D, et al. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer, 2001,86:827-830.
3Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol, 2001,19:4298-4303.
4Edler D, Glimelius B, Hallstrm M, et al. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol, 2002,20:1721-1728.
5Elsaleh H, Grieu F, Joseph D, et al. Thymidylate synthase genotype and survival benefit from chemotherapy in patients with colorectal cancer. Proc Am Soc Clin Oncol, 2001, 20:124a(abstr493).
6Allegra CJ, Paik S, Parr A, et al. Prognostic value of thymidylate synthase(TS) , Ki-67 and p53 in patients with Dukes′B & C colon cancer. Proc Am Soc Clin Oncol, 2001, 20:124a(abstr491).
7Allegra CJ, Parr AL, Wold LE, et al. Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol, 2002,20:1735-1743.
8Pullarkat ST, Ghaderi V, Ingles SA, et al. Human thymidylate synthase gene polymorphism determines response to 5-FU chemotherapy. Proc Am Soc Clin Oncol, 2000, 19:243a(abstr942).
9Marsh S,Collie-Duguid ESR,Li T,et al.Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian population [J].Genomics,1999,58:310 -312.
10Horie N,Aiba H,Oguro K,et al.Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5 '-terminal regulatory region of the human gene for thymidylate synthase[J].Cell Struct Funct,1995,20:191 -197.
2Shibata J, Aiba K, Shibata H, et al. Detection and quantitation of thymidylate synthase mRNA in human colon adenocarcinoma cell line resistant to 5 - fluorouracil by competitive PCR[ J]. Anticancer Research, 1998,18 (3) : 1457 - 1463.
3Sanguedolce R,Alessandro R, De-Leo G, et al. Failure of detection of the tyrosine to histidine substitution at the residue 33 of thymidylate synthase in human colorectal cancer. A preliminary study[J]. Anticancer Research,2000,20 ( 6 ) :4347 - 4350.
4Berger SH,Berger FG. Thymidylate synthase as a determinant of 5- fluoro - 2' - deoxyuridine response in human colonic tumor cell lines[ J]. Molecular Pharmacology,19$8,34(4) :474 -479.
5Bertino JR, Banerjee D. Is the measurement of thymidylate synthase to determine suitability for treatment with 5 - fluoropyrimidines ready for prime time.'? [ J ]. Clinical Cancer Research, 2003,9 (4) : 1235 - 1239.
6Di-Paolo A,Chu E. The role of thymidylate synthase as a molecular biomarker[ J ]. Clinical Cancer Research ,2004,10 ( 2 ) :411 - 412.
7Popat S,Matakidou A, Houlston RS. Thymidylate-synthase expres- sion and prognosis in colorectal cancer: a systematic review and meta-analysis [ J ]. Journal of Clinical Oncology,2004,22 ( 3 ) : 529 -536.
8Findlay MPN,Cunningham D, Morgan G, et al. Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy[ J]. European Journal of Cancer,2005,41:2176 - 2183.
